Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.
ADAM17
bevacizumab treatment
immunohistochemistry
ovarian cancer
prognostic biomarker
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
received:
18
07
2022
revised:
20
08
2022
accepted:
29
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has been involved in ovarian cancer development, progression and cell resistance to cisplatin. Tissue microarrays from 309 ovarian cancer patients enrolled in the MITO16A/MANGO-OV2 clinical trial were analyzed by immunohistochemistry for ADAM17 protein expression. Intensity and extent of staining were combined into a semi-quantitative visual grading system (H score) which was related to clinicopathological characteristics of cases and the clinical outcome of patients by univariate and multivariate Cox regression models. ADAM17 immunostaining was detected in most samples, mainly localized in the tumor cells, with variable intensity across the cohort. Kaplan-Meier survival curves, generated according to the best cut-off value for the ADAM17 H score, showed that high ADAM17 expression was associated with worse prognosis for PFS and OS. However, after the application of a shrinkage procedure to adjust for overfitting hazard ratio estimates, the ADAM17 value as prognostic factor was lost. As subgroup analysis suggested that ADAM17 expression could be prognostically relevant in cases with no residual disease at baseline, further studies in this patient category may be worth planning.
Identifiants
pubmed: 36140519
pii: diagnostics12092118
doi: 10.3390/diagnostics12092118
pmc: PMC9498026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 5776
Organisme : Italian Ministry of Health
ID : Ricerca Corrente and 5x1000 Funds
Organisme : Associazione Italiana Di Oncologia Medica
ID : To S.P.
Références
Oncotarget. 2018 Mar 23;9(22):16043-16058
pubmed: 29662625
Differentiation. 2007 Nov;75(9):800-8
pubmed: 17608729
PLoS One. 2012;7(12):e50791
pubmed: 23251384
Cancer Res. 1988 Sep 1;48(17):5023-8
pubmed: 3165707
Oncogene. 2012 Aug 2;31(31):3621-34
pubmed: 22105359
EMBO J. 2003 Mar 3;22(5):1114-24
pubmed: 12606576
Oncol Lett. 2019 Jun;17(6):4914-4920
pubmed: 31186700
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Exp Cell Res. 2017 Oct 1;359(1):185-194
pubmed: 28754469
Urol Oncol. 2014 Nov;32(8):1272-6
pubmed: 24996774
Genet Mol Res. 2015 Apr 30;14(2):4391-8
pubmed: 25966212
Acta Histochem. 2012 Feb;114(2):131-9
pubmed: 21501859
Mol Carcinog. 2012 Feb;51(2):150-64
pubmed: 21480393
J Surg Res. 2017 Dec;220:223-233
pubmed: 29180185
Int J Gynecol Cancer. 2019 May 2;:
pubmed: 31048403
Nature. 1999 Dec 23-30;402(6764):884-8
pubmed: 10622253
BMC Cancer. 2014 Jul 19;14:520
pubmed: 25038797
Curr Pharm Des. 2009;15(20):2319-35
pubmed: 19601834
J Biol Chem. 2017 Apr 14;292(15):6339-6351
pubmed: 28232483
Tumour Biol. 2014 Aug;35(8):7575-86
pubmed: 24793016
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Stat Med. 2004 Jun 15;23(11):1701-13
pubmed: 15160403
N Engl J Med. 2019 Dec 19;381(25):2471-2474
pubmed: 31851805
J Neurooncol. 2020 Apr;147(2):327-337
pubmed: 32170633
Cancers (Basel). 2021 Oct 14;13(20):
pubmed: 34680301
Mol Med Rep. 2015 Feb;11(2):961-7
pubmed: 25351873
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922533
Clin Cancer Res. 2005 Jul 1;11(13):4783-92
pubmed: 16000575
Exp Cell Res. 2018 Sep 15;370(2):373-382
pubmed: 29966664
Ann Oncol. 2008 Jun;19(6):1075-81
pubmed: 18238782
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Cancers (Basel). 2021 Nov 06;13(21):
pubmed: 34771725
Clin Transl Oncol. 2015 Aug;17(8):604-11
pubmed: 25786367
Cells. 2020 Apr 07;9(4):
pubmed: 32272732
Curr Drug Targets. 2016;17(16):1908-1927
pubmed: 27469341
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Ann Surg. 2012 Dec;256(6):1014-22
pubmed: 22668812
PLoS One. 2015 Jul 15;10(7):e0132661
pubmed: 26176220
Circ Res. 2010 Mar 19;106(5):932-40
pubmed: 20110534
Med Oncol. 2012 Dec;29(4):2684-90
pubmed: 22139867
Clin Cancer Res. 2008 Feb 15;14(4):1182-91
pubmed: 18281553
J Cell Biol. 2004 Mar 1;164(5):769-79
pubmed: 14993236
Oncogene. 2016 Jan 28;35(4):438-47
pubmed: 25915843
Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43
pubmed: 15688065
Crit Rev Oncol Hematol. 2019 Aug;140:67-72
pubmed: 31176273
Trends Immunol. 2011 Aug;32(8):380-7
pubmed: 21752713
Mol Cancer Res. 2007 Dec;5(12):1246-53
pubmed: 18171982
Pathol Res Pract. 2019 Jun;215(6):152410
pubmed: 30992230
BMC Cancer. 2018 May 18;18(1):570
pubmed: 29776401
Tumour Biol. 2013 Jun;34(3):1813-8
pubmed: 23475633
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
PLoS One. 2012;7(7):e40597
pubmed: 22792380
Oncol Rep. 2007 Jun;17(6):1541-9
pubmed: 17487416
Crit Rev Biochem Mol Biol. 2010 Apr;45(2):146-69
pubmed: 20184396
Am J Clin Pathol. 2008 May;129(5):735-43
pubmed: 18426733
Int J Gynecol Cancer. 2021 Jun;31(6):875-882
pubmed: 33931498
Angiogenesis. 2015 Jan;18(1):13-22
pubmed: 25218057